How Big Pharma’s China Trials Are Escaping Scrutiny
U.S. supply chains with connections to Xinjiang and the Chinese military are heavily regulated — just not for pharmaceuticals.
Nurses prepare for infusion and injection at a hospital in Cangxian county, Cangzhou city, north Chinas Hebei province. Credit: IC Photo via Depositphotos
U.S. sanctions on Chinese companies operating in Xinjiang or with the Chinese military have reshaped supply chains from agriculture to technology. It’s a different story for the pharmaceutical industry.
For multinational drugmakers with R&D investments and human trials running at Chinese hospitals, there is no regulation prohibiting drug development or clinical testing in a region otherwise subject to a range of existing U.S. sanctions and restrictions.
Data put together by The
Exclusive longform investigative journalism, Q&As, news and analysis, and data on Chinese business elites and corporations. We publish China scoops you won't find anywhere else.
A weekly curated reading list on China from Andrew Peaple.
A daily roundup of China finance, business and economics headlines.
We offer discounts for groups, institutions and students. Go to our Subscriptions page for details.
The U.S. and EU are restricting Chinese inverters over cybersecurity and supply-chain concerns, but replacing them may create new challenges for the renewable-energy industry.
The former Trump official argues that the president’s approach to China is working, and explains why time is on the American side as the U.S. and China continue to move apart.
Corporate Risk Intelligence for National Security, Compliance & Due Diligence
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
